Summit Therapeutics Inc.
SMMT
$24.76
$0.803.34%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -62.91M | -61.20M | -56.25M | -60.39M | -43.47M |
| Total Depreciation and Amortization | 25.00K | 22.00K | 20.00K | 20.00K | 27.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.91M | 13.19M | 16.97M | 24.36M | 9.11M |
| Change in Net Operating Assets | -6.19M | -686.00K | 8.96M | 3.00M | 4.20M |
| Cash from Operations | -61.17M | -48.67M | -30.30M | -33.00M | -30.13M |
| Capital Expenditure | -422.00K | -14.00K | -58.00K | -63.00K | -4.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 160.53M | 83.50M | -108.56M | -200.02M | 19.88M |
| Cash from Investing | 160.11M | 83.48M | -108.62M | -200.08M | 19.87M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -24.50M | -75.50M | -- | -- |
| Issuance of Common Stock | 7.68M | 888.00K | 279.64M | 200.21M | 485.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 7.68M | -23.61M | 204.14M | 200.21M | 485.00K |
| Foreign Exchange rate Adjustments | 38.00K | -108.00K | 114.00K | 12.00K | -36.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 106.66M | 11.09M | 65.34M | -32.86M | -9.81M |